STEEPLE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
Line 24: | Line 24: | ||
* [[Hematoma]] >5 cm or leading to prolonged or new hospitalization | * [[Hematoma]] >5 cm or leading to prolonged or new hospitalization | ||
*Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | *Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | ||
Uncontrolled bleeding requiring protamine sulfate administration}} | *Uncontrolled bleeding requiring protamine sulfate administration}} | ||
== References == | == References == |
Revision as of 17:35, 27 March 2013
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation [1] Major Bleeding
Minor
|
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.